Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 6liposomal doxorubicin 4Carboplatin 4Topotecan 3Drug Therapy 3Gemcitabine 2Doxorubicin 2Bevacizumab 21-dodecylpyridoxal 2trametinib 1saracatinib 1pertuzumab 1pembrolizumab 1pegfilgrastim 1olaparib 1masitinib 1dabrafenib 1cyclopropapyrroloindole 1cobimetinib 1cediranib 1atezolizumab 1aflibercept 1abagovomab 1Vemurafenib 1Trastuzumab 1Taxes 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1NP-G2-044 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Ovarian Neoplasms × NP-G2-044 × Clear all
NCT07109414 2026-03-09

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Novita Pharmaceuticals, Inc.

Phase 2/3 Active not recruiting
380 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡